The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

Clesrovimab joins the monoclonal antibody nirsevimab (Beyfortus), as well as the maternal bivalent RSV prefusion F protein ...

RSV is responsible for around 1 lakh deaths, over 3.6 million hospitalisations in children under age of 5 every year, ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.

People in Northern Ireland are being reminded that a potentially life-saving vaccination aimed at protecting newborns and ...

The number of Australians vaccinated against influenza is "worryingly low", health experts say, as new data reveal the winter ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's ...

Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...